Drug Manufacture InnoCare’s Tafasitamab Combo for Blood Cancer ApprovedBy MohamedMis2July 17, 2023 InnoCare Pharmaceuticals Ltd. achieves a significant milestone as the Hong Kong Department of Health approves the use of tafasitamab. This…
Financial Advancing Towards Myelofibrosis BreakthroughBy MohamedMis2July 12, 2023 MorphoSys is on track to complete its Phase 3 myelofibrosis program 16% faster than originally planned. [1] However, there is…
Drug Manufacture InnoCare Revolutionizes Blood Cancer TreatmentBy MohamedMis2July 7, 2023 InnoCare, a leading biopharmaceutical company, has received approval in Hong Kong for the use of its tafasitamab combination therapy in…
